A healthy investment

RIBOPRO is rapidly growing through a combination of increasing sales (volume & order size), and well-controlled costs. We achieve cost control by backward integration of critical and costly raw materials (e.g. enzymes & custom lipids), automated manufacturing, and the use of smart software to minimize administrative burden. Through in-house R&D, we continuously find new and more efficient ways to approach manufacturing & other business processes.
Even more importantly, we are rapidly building a patent portfolio around key ingredients required for more advanced uses of mRNA, creating increasing licensing opportunities.

Revenues: 10x (’20-’21), 3x (’21-’22) from R&D-grade mfg. services
Runway: until break-even mid ’23 => Looking for funding to accelerate
Supply: Increasingly self-sufficient by in-house mfg. of raw materials
Gross margin: >50% => >90%
Growing pipeline for GMP-manufacturing (5-10x of R&D revenues)
Licensing opportunities: >€10B expected from growing patent portfolio
FTE: approaching 30

HQ: Pivot Park, Oss, the Netherlands
– Production facility R&D-grade
– Research laboratories (incl. BSL-2)
– Offices

R3: Oss, the Netherlands
– Engineering facility
– Offices

GMP: Medace, Maastricht, the Netherlands
– Production facility GMP-grade
– Class A & C cleanrooms (ISO14644)
– QC-laboratory
– Microbiology lab (BSL-1)

mRNA technologies
– De-immunization (sequence optimisation) – patented
– 5’UTR & 3’UTR libraries – trade-secret => patent
– Undisclosed technologies in development

Delivery technologies
– Novel class of ionizable lipids – patented
– Novel core lipid system => patent
– Undisclosed technologies in development

Manufacturing technologies
– Co-transcriptional capping method => patent
– Novel RNAP variants with low dsRNA => patent
– Novel DNA amplification method => patent
– Undisclosed technologies in development

RIBOPRO is an innovative, premium CDMO and technology provider.
We provide the following products & services:

Core service:
1. mRNA design
2. de novo DNA template synthesis (via partners)
3. DNA cloning & amplification (in-house)
4. In vitro transcription (IVT), purification and modification of mRNA
5. LNP-formulation
6. Shipping (via partners)

Additional services:
1. Consultancy on experimental design/data
2. Consultancy on clinical trial design (coming in 2023)
3. CRO-services of specified assays (in-house)
4. GMP-manufacturing (coming in Q1 2023)
5. Out-licensing of technologies
6. Commercial-manufacturing (coming in 2024)

The additional services are provided to help customers reach the market/patient, thereby activating RIBOPRO’s royalties model.

RIBOPRO aims to raise €16.5mio for the following uses:

1. Increasing our speed (USP)
by shortening the turn-around of the de novo DNA step

2. Capturing market share
a. Sample distribution (seeing is believing)
b. Increased marketing
c. Secondary facilities

3. Maintain/expand technology leadership
a. mRNA tech R&D
b. LNP tech R&D
c. Special mRNA products
d. Research collaborations
e. IP-acquisitions

4. Data collection
a. Pre-clinical (GLP) data package on proprietary products5. Micellaneous
a. Develop the Byte-to-nucleotide(TM) platform
b. Buffer

RIBOPRO is happy to have the following syndicate of investors for financial, strategic and practical support:
1. Stichting Vlasroot (business angel group)
2. BOM (regional investment fund)
3. Rockstart Health (VC)
4. Private investors